Given the pivotal role of the K-Ras pathway in pancreatic cancer and the complexities associated with directly targeting K-Ras due to its non-enzymatic nature, these findings propose a novel approach to disrupting this pathway through targeting 5-Lox with specific agents like MK591. This evidence concerns the gene KRAS and pancreatic neoplasm.